我国上市后个例安全性报告实施E2B(R3)思路及探讨
侯永芳, 方恺睿, 漆燕, 王青, 刘红亮
Thoughts on Implementing E2B(R3) in Individual Case Safety Reports in China
HOU Yongfang, FANG Kairui, QI Yan, WANG Qing, LIU Hongliang
中国药物警戒
.
2019, (10): 588
-590
.
DOI: 10.19803/j.1672-8629.2019.10.03
